El monitoreo continuo de glucosa (MCG) le brinda un panorama más completo de sus niveles de glucosa, lo que puede resultar en mejores decisiones acerca de su estilo de vida y un mejor control de la glucosa.
Un medidor de glucosa en la sangre solo proporciona una “lectura instantánea” de su nivel de glucosa en un momento dado. El sistema de MCG le brinda un panorama más amplio de las tendencias de glucosa. El MCG puede proporcionar información valiosa1 en momentos cruciales del día, por ejemplo, antes y durante la realización de ejercicio físico, antes de conducir, antes de realizar una prueba o un examen y en medio de la noche.
El MCG es especialmente beneficioso para las personas que reúnen las siguientes características:2
Ya sea que trate la diabetes con una bomba, múltiples inyecciones diarias, medicamentos por vía oral o a través de la alimentación y el ejercicio físico¶, Medtronic ofrece productos de MCG y sistemas de bomba de insulina que les brindan a usted, sus seres queridos y los profesionales de atención médica los conocimientos necesarios para medir y tratar la diabetes a su manera.
Para solicitar una verificación de cobertura de seguro gratuita y obtener más información sobre su elegibilidad y los posibles costos de desembolso, complete el siguiente formulario o llame al 1-888-350-5440 y uno de nuestros asesores en el tratamiento de la diabetes estará encantado de ayudarlo.
* Solo el MCG inteligente Guardian™ Connect y el MCG profesional iPro2™ se pueden usar sin una bomba de insulina.
¶ El acceso depende del diseño del plan médico.
1 El sistema está diseñado para complementar, no para reemplazar, la información obtenida de los dispositivos estándar de monitoreo de glucemia. Todos los ajustes de la terapia deben basarse en las mediciones obtenidas con los dispositivos estándar de monitoreo de glucemia y no en los valores proporcionados por el sistema.
2 Grunberger G, Bailey TS, Cohen AJ, et al; and AACE Insulin Pump Management Task Force. Statement by the American Association of Clinical Endocrinologists Consensus Panel on insulin pump management. Endocr Pract. 2010;16(4):746-762.
Important Safety Information: Guardian™ Connect CGM System
The Guardian™ Connect system requires a prescription and is indicated for continuous or periodic monitoring of glucose levels in the interstitial fluid under the skin, in patients (14 to 75 years of age) with diabetes mellitus. The system is intended to complement, not replace, information obtained from standard blood glucose monitoring devices, and is not recommended for people who are unwilling or unable to perform a minimum of two meter blood glucose tests per day, or for people who are unable or unwilling to maintain contact with their healthcare professional. The system requires a functioning mobile electronic device with correct settings. If the mobile device is not set up or used correctly, you may not receive sensor glucose information or alerts. For complete details of the system and its components, including warnings, contraindications, and precautions, please consult the user guide at http://www.medtronicdiabetes.com/support/download-library/user-guides and http://www.medtronicdiabetes.com/importantsafetyinformation.
The Medtronic MiniMed™ 770G System consists of the following devices: MiniMed™ 770G Insulin Pump, the Guardian™ Link (3) Transmitter, the Guardian™ Sensor (3), one-press serter, the Accu-Chek® Guide Link blood glucose meter, and the AccuChek®Guide Test Strips. The system requires a prescription.
The Guardian™ Sensor (3) has not been evaluated and is not intended to be used directly for making therapy adjustments, but rather to provide an indication of when a fingerstick may be required. All therapy adjustments should be based on measurements obtained using a blood glucose meter and not on values provided by the Guardian™ Sensor (3).
All therapy adjustments should be based on measurements obtained using the Accu-Chek® Guide Link blood glucose meter and not on values provided by the Guardian™ Sensor (3). Always check the pump display to ensure the glucose result shown agrees with the glucose results shown on the Accu-Chek® Guide Link blood glucose meter. Do not calibrate your CGM device or calculate a bolus using a blood glucose meter result taken from an alternative site. It is not recommended to calibrate your CGM device when sensor or blood glucose values are changing rapidly, e.g., following a meal or physical exercise.
WARNING: Do not use the SmartGuard™ Auto Mode for people who require less than 8 units or more than 250 units of total daily insulin per day. A total daily dose of at least 8 units, but no more than 250 units, is required to operate in SmartGuard™ Auto Mode.
WARNING: Do not use the MiniMed™ 770G system until appropriate training has been received from a healthcare professional. Training is essential to ensure the safe use of the MiniMed™ 770G system.
Pump therapy is not recommended for people whose vision or hearing does not allow recognition of pump signals and alarms. Pump therapy is not recommended for people who are unwilling or unable to maintain contact with their healthcare professional. The safety of the MiniMed™ 770G system has not been studied in pregnant women. For complete details of the system, including product and important safety information such as indications, contraindications, warnings and precautions associated with system and its components, please consult https://www.medtronicdiabetes.com/important-safetyinformation#minimed-770g and the appropriate user guide at https://www.medtronicdiabetes.com/download-library